Overview and Scope
Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.
Sizing and Forecast
The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in elderly population and economic growth in emerging markets.
The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increase in healthcare access, rising prevalence of caner and increasing demand for antisense and rnai therapeutics due to covid-19. Major trends in the forecast period include focus efforts towards the research and development of rna therapeutics for orphan diseases, use of nanoparticles, develop new and improved antisense and rnai therapeutics, and collaborate with other companies for product innovation and to drive revenues.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report
Segmentation & Regional Insights
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
North America was the largest region in the antisense & RNAi therapeutics market in 2023. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Major Driver Impacting Market Growth
The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, 6.2 million people may have Alzheimer’s disease in the USA . As per January 2023 data approximately 500,000 people in the USA are diagnosed with Parkinson’s disease. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.
Key Industry Players
Major companies operating in the antisense & rnai therapeutics market report are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical
The antisense & rnai therapeutics market report table of contents includes:
1. Executive Summary
- Antisense & RNAi Therapeutics Market Characteristics
- Antisense & RNAi Therapeutics Market Trends And Strategies
- Antisense & RNAi Therapeutics Market – Macro Economic Scenario
- Global Antisense & RNAi Therapeutics Market Size and Growth
.
- Global Antisense & RNAi Therapeutics Market Competitive Benchmarking
- Global Antisense & RNAi Therapeutics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market
- Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
